Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis

  • Akiyoshi Kasuga
  • Yasuo Hamamoto
  • Ayano Takeuchi
  • Naohiro Okano
  • Kazuhiro Togasaki
  • Yu Aoki
  • Takeshi Suzuki
  • Kenta Kawasaki
  • Kenro Hirata
  • Yasutaka Sukawa
  • Takanori Kanai
  • Hiromasa Takaishi
REVIEW
  • 80 Downloads

Summary

Background Post-progression survival (PPS) could be a confounding element in interpreting data from clinical trials of second-line chemotherapy in patients with advanced pancreatic cancer (PC) previously treated with gemcitabine (GEM) because a recent meta-analysis of oxaliplatin combination therapy showed statistical heterogeneity for overall survival (OS) but not for progression-free survival (PFS). This study aimed to improve the understanding of the impact of PPS on OS in this setting. Methods Databases were searched to identify randomized controlled trials (RCTs) in the salvage setting. We evaluated relationships between OS and PFS, PPS, and other variables. Results Totally, 17 RCTs with 3253 patients were identified. Median OS was strongly and moderately associated with median PPS and PFS, respectively (r = 0.913; p < 0.001 and 0.780; p < 0.001, respectively). The proportion of patients with good performance status was significantly associated with both PPS and PFS (r = 0.574, p < 0.001 and 0.492, p < 0.001, respectively). The induction rate of subsequent chemotherapy was related to the duration of PPS and OS (r = 0.640, p < 0.001 and 0.647, p < 0.001, respectively). Median PPS and OS were significantly longer in recent trials than those in older trials (3.55 versus 2.78 months, p < 0.001 and 6.29 versus 5.02 months, p < 0.001). Conclusions Median PPS was strongly correlated with median OS. Given the recently increased opportunity for subsequent chemotherapy and supportive care, PPS may serve as an important element to clarify problems in this setting.

Keywords

Pancreatic cancer Meta-analysis Randomized controlled trial Second-line chemotherapy Salvage chemotherapy Post-progression survival 

Notes

Compliance with ethical standards

Conflict of interest

All authors declare no Conflicts of Interests for this article.

Takanori Kanai received research grants from Astellas Pharm Inc., Astra-Zeneca K.K., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eisai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Tanabe Mitsubishi Pharmaceutical Co. Ltd., JIMRO Co. Ltd., Kyorin Pharmaceutical Co. Ltd., and received service honoraria from Astellas Pharm Inc., Eisai Pharmaceutical Co. Ltd., JIMRO Co. Ltd., Tanabe Mitsubishi Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Miyarisan Pharmaceutical Co. Ltd., and Zeria Pharmaceutical Co. Ltd. Hiromasa Takaishi received research grants from Taiho Pharmaceutical Co. Ltd., and Yakult Honsha Pharmaceutical Co. Ltd., outside the submitted work.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

We did not use individual data but published data. These data have been widely utilized in research and are generally available. Therefore, we confirm that any aspect of the work covered in this manuscript has been conducted with ethical approval. And this study is registered in the PROSPERO database (CRD42017071274) and was conducted according to the Preferred Reporting Items for Systemic Reviews and Meta-Analysis (PRISMA) statement.

References

  1. 1.
    Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E (2017) European cancer mortality predictions for the year 2017, with focus on lung cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO 28(5):1117–1123.  https://doi.org/10.1093/annonc/mdx033 CrossRefGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30.  https://doi.org/10.3322/caac.21332 CrossRefPubMedGoogle Scholar
  3. 3.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90.  https://doi.org/10.3322/caac.20107 CrossRefPubMedGoogle Scholar
  4. 4.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703.  https://doi.org/10.1056/NEJMoa1304369 CrossRefGoogle Scholar
  5. 5.
    Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (19):1817–1825. doi: https://doi.org/10.1056/NEJMoa1011923
  6. 6.
    Kasuga A, Hamamoto Y, Takeuchi A, Kawasaki K, Suzuki T, Hirata K, Sukawa Y, Takaishi H, Kanai T (2017) Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy. Cancer Chemother Pharmacol 79(3):595–602.  https://doi.org/10.1007/s00280-017-3263-3 CrossRefPubMedGoogle Scholar
  7. 7.
    Kawakami H, Okamoto I, Hayashi H, Taguri M, Morita S, Nakagawa K (2013) Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. Eur J Cancer (Oxford, England : 1990) 49(14):3003–3009.  https://doi.org/10.1016/j.ejca.2013.05.022 CrossRefGoogle Scholar
  8. 8.
    Terashima T, Yamashita T, Takata N, Nakagawa H, Toyama T, Arai K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S (2016) Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. Hepatology Research : the Official Journal of the Japan Society of Hepatology 46(7):650–656.  https://doi.org/10.1111/hepr.12601 CrossRefGoogle Scholar
  9. 9.
    Petrelli F, Barni S (2013) Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO 24(1):186–192.  https://doi.org/10.1093/annonc/mds289 CrossRefGoogle Scholar
  10. 10.
    Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dorken B, Riess H, Oettle H (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer (Oxford, England : 1990) 47(11):1676–1681.  https://doi.org/10.1016/j.ejca.2011.04.011 CrossRefGoogle Scholar
  11. 11.
    Wang-Gillam A, Li C-P, Bodoky G, Dean A, Shan Y-S, Jameson G, Macarulla T, Lee K-H, Cunningham D, Blanc JF, Hubner RA, Chiu C-F, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen L-T (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387(10018):545–557.  https://doi.org/10.1016/s0140-6736(15)00986-1 CrossRefPubMedGoogle Scholar
  12. 12.
    Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Gorner M, Molle M, Greten TF, Lakner V, Bischoff S, Sinn M, Dorken B, Pelzer U (2014) Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol Off J Am Soc Clin Oncol 32(23):2423–2429.  https://doi.org/10.1200/jco.2013.53.6995 CrossRefGoogle Scholar
  13. 13.
    Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, Zalewski P, Do T, Cano P, Lam WY, Dowden S, Grassin H, Stewart J, Moore M (2016) PANCREOX: a randomized phase III study of 5-fluorouracil/Leucovorin with or without Oxaliplatin for second-line advanced pancreatic Cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 34:3914–3920.  https://doi.org/10.1200/JCO.2016.68.5776 CrossRefGoogle Scholar
  14. 14.
    Ohkawa S, Okusaka T, Isayama H, Fukutomi A, Yamaguchi K, Ikeda M, Funakoshi A, Nagase M, Hamamoto Y, Nakamori S, Tsuchiya Y, Baba H, Ishii H, Omuro Y, Sho M, Matsumoto S, Yamada N, Yanagimoto H, Unno M, Ichikawa Y, Takahashi S, Watanabe G, Wakabayashi G, Egawa N, Tsuda M, Hosotani R, Hamada C, Hyodo I (2015) Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 112(9):1428–1434.  https://doi.org/10.1038/bjc.2015.103 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Sonbol MB, Firwana B, Wang Z, Almader-Douglas D, Borad MJ, Makhoul I, Ramanathan RK, Ahn DH, Bekaii-Saab T (2017) Second-line treatment in patients with pancreatic ductal adenocarcinoma: a meta-analysis. Cancer 123:4680–4686.  https://doi.org/10.1002/cncr.30927 CrossRefPubMedGoogle Scholar
  16. 16.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 327(7414):557–560.  https://doi.org/10.1136/bmj.327.7414.557 CrossRefGoogle Scholar
  17. 17.
    Saad ED, Katz A, Buyse M (2010) Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol Off J Am Soc Clin Oncol 28(11):1958–1962.  https://doi.org/10.1200/jco.2009.25.5414 CrossRefGoogle Scholar
  18. 18.
    Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K (2012) Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO 23(6):1537–1541.  https://doi.org/10.1093/annonc/mdr487 CrossRefGoogle Scholar
  19. 19.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRefPubMedGoogle Scholar
  20. 20.
    Ulrich-Pur H, Raderer M, Verena Kornek G, Schull B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Scheithauer W (2003) Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 88(8):1180–1184.  https://doi.org/10.1038/sj.bjc.6600883 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Jacobs AD, Burris HA, Rivkin S, Ritch PS, Eisenberg PD, Mettinger KL (2004) A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a north-American multi-center study. J Clin Oncol 22(14_suppl):4013–4013.  https://doi.org/10.1200/jco.2004.22.14_suppl.4013 CrossRefGoogle Scholar
  22. 22.
    Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC, Lee JL (2009) A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 101(10):1658–1663.  https://doi.org/10.1038/sj.bjc.6605374 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Ioka T, Katayama K, Ishida N, Takada R, Yamai T, Fukutake N, Ashida R, Uehara H, Ohigashi H, Takahashi H, Ishikawa O (2013) Randomized phase II study of best available fluoropyrimidine compared with continuation of gemcitabine (gem) monotherapy in patients with gem-refractory pancreatic cancer. J Clin Oncol 31(4_suppl):287–287.  https://doi.org/10.1200/jco.2013.31.4_suppl.287 CrossRefGoogle Scholar
  24. 24.
    oral presentations (2010). Annals of Oncology 21(suppl_6):vi11–vi19.  https://doi.org/10.1093/annonc/mdq268
  25. 25.
    Ioka T, Komatsu Y, Mizuno N, Tsuji A, Ohkawa S, Tanaka M, Iguchi H, Ishiguro A, Kitano M, Satoh T, Yamaguchi T, Takeda K, Kida M, Eguchi K, Ito T, Munakata M, Itoi T, Furuse J, Hamada C, Sakata Y (2017) Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 116(4):464–471.  https://doi.org/10.1038/bjc.2016.436 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wang M, Shi SB, Qi JL, Tang XY, Tian J (2013) S-1 plus CIK as second-line treatment for advanced pancreatic cancer. Med Oncol 30(4):747.  https://doi.org/10.1007/s12032-013-0747-9 CrossRefPubMedGoogle Scholar
  27. 27.
    Ueno M, Okusaka T, Omuro Y, Isayama H, Fukutomi A, Ikeda M, Mizuno N, Fukuzawa K, Furukawa M, Iguchi H, Sugimori K, Furuse J, Shimada K, Ioka T, Nakamori S, Baba H, Komatsu Y, Takeuchi M, Hyodo I, Boku N (2016) A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology / ESMO 27(3):502–508.  https://doi.org/10.1093/annonc/mdv603 CrossRefGoogle Scholar
  28. 28.
    Ge F, Xu N, Bai Y, Ba Y, Zhang Y, Li F, Xu H, Jia R, Wang Y, Lin L, Xu J (2014) S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study. Oncologist 19(11):1133–1134.  https://doi.org/10.1634/theoncologist.2014-0223 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM 3rd, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Manges R, Garrett WM, Hunter DS, Clark J, Leopold L, Sandor V, Levy RS (2015) Randomized, double-blind, phase II study of Ruxolitinib or placebo in combination with Capecitabine in patients with metastatic pancreatic Cancer for whom therapy with gemcitabine has failed. J Clin Oncol Off J Am Soc Clin Oncol 33(34):4039–4047.  https://doi.org/10.1200/JCO.2015.61.4578 CrossRefGoogle Scholar
  30. 30.
    Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and fluorouracil in patients with metastatic pancreatic Cancer after prior therapy: SWOG S1115 study randomized clinical trial. JAMA Oncology 3(4):516–522.  https://doi.org/10.1001/jamaoncol.2016.5383 CrossRefPubMedGoogle Scholar
  31. 31.
    Ueno M, Ohkawa S, Kobayashi N, Sugimori K, Kawaguchi Y, Kobayashi S, Taguri M, Yamanaka T, Mine T (2017) Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 35(4_suppl):429–429.  https://doi.org/10.1200/JCO.2017.35.4_suppl.429 CrossRefGoogle Scholar
  32. 32.
    Ueno M, Ioka T, Ueno H, Park JO, Chang H-M, Sasahira N, Kanai M, Chung I-J, Ikeda M, Nakamori S, Mizuno N, Omuro Y, Yamaguchi T, Hara H, Sugimori K, Furuse J, Takeuchi M, Okusaka T, Boku N, Hyodo I (2017) TAS-118 (S-1 plus leucovorin) versus S-1 in gemcitabine-refractory advanced pancreatic cancer: A randomized, open-label, phase III trial (GRAPE trial). J Clin Oncol 35(15_suppl):4099–4099.  https://doi.org/10.1200/JCO.2017.35.15_suppl.4099 Google Scholar
  33. 33.
    Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, Macarulla T, Sahai V, Sama A, Greeno E, Yu KH, Verslype C, Dawkins F, Walker C, Clark J, O'Reilly EM (2018) Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Investig New Drugs.  https://doi.org/10.1007/s10637-018-0580-2
  34. 34.
    Kasuga A, Okano N, Naruge D, Kitamura H, Takasu A, Nagashima F, Furuse J (2015) Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival. Cancer Chemother Pharmacol 75(3):457–464.  https://doi.org/10.1007/s00280-014-2665-8 CrossRefPubMedGoogle Scholar
  35. 35.
    Sinn M, Dalken L, Striefler JK, Bischoff S, Schweitzer N, Pelzer U, Dorken B, Riess H, Stieler JM (2016) Second-line treatment in pancreatic Cancer patients: who profits?--results from the CONKO study group. Pancreas 45(4):601–605.  https://doi.org/10.1097/mpa.0000000000000533 CrossRefPubMedGoogle Scholar
  36. 36.
    Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, Heyd B, Cleau D, d'Engremont C, Dupont-Gossart AC, Lakkis Z, Tournigand C, Bouche O, Rousseau B, Neuzillet C, Bonnetain F, Borg C, Vernerey D (2017) Overall survival prediction and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma. J Natl Cancer Inst 109(10).  https://doi.org/10.1093/jnci/djx037
  37. 37.
    Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489–495.  https://doi.org/10.1016/s1470-2045(10)70218-7 CrossRefPubMedGoogle Scholar
  38. 38.
    Ouyang H, Ma W, Liu F, Yue Z, Fang M, Quan M, Pan Z (2017) Factors influencing survival of patients with pancreatic adenocarcinoma and synchronous liver metastases receiving palliative care. Pancreatology : Official Journal of the International Association of Pancreatology 17(5):773–781.  https://doi.org/10.1016/j.pan.2017.07.002 CrossRefGoogle Scholar
  39. 39.
    Iino C, Shimoyama T, Igarashi T, Aihara T, Ishii K, Sakamoto J, Tono H, Fukuda S (2017) Biliary drainage improves the predictive value of modified Glasgow prognostic scores in inoperable pancreatic cancer. PLoS One 12(6):e0178777.  https://doi.org/10.1371/journal.pone.0178777 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Hayashi H, Okamoto I, Taguri M, Morita S, Nakagawa K (2013) Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. Clin Lung Cancer 14(3):261–266.  https://doi.org/10.1016/j.cllc.2012.09.006 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Akiyoshi Kasuga
    • 1
  • Yasuo Hamamoto
    • 1
  • Ayano Takeuchi
    • 2
  • Naohiro Okano
    • 3
  • Kazuhiro Togasaki
    • 1
  • Yu Aoki
    • 1
  • Takeshi Suzuki
    • 1
  • Kenta Kawasaki
    • 1
  • Kenro Hirata
    • 1
  • Yasutaka Sukawa
    • 1
  • Takanori Kanai
    • 1
  • Hiromasa Takaishi
    • 1
  1. 1.Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of MedicineKeio UniversityTokyoJapan
  2. 2.Department of Preventive Medicine and Public Health, School of MedicineKeio UniversityTokyoJapan
  3. 3.Department of Clinical Oncology, School of MedicineKyorin UniversityTokyoJapan

Personalised recommendations